Summary of Study ST000138
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000123. The data can be accessed directly via it's Project DOI: 10.21228/M8PC7J This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST000138 |
| Study Title | Targeted LC MS of acylcarnitines: TLCMS |
| Study Summary | Acylcarnitines (panel of 66 quantitated acylcarnitines) analyzed by LC/MS/MS using flow injection analysis with electrospray ionization |
| Institute | University of Florida |
| Department | Pharmacotherapy and Translational Research |
| Last Name | Cooper-DeHoff |
| First Name | Rhonda |
| dehoff@cop.ufl.edu | |
| Submit Date | 2015-01-08 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | d |
| Uploaded File Size | 1.3 G |
| Analysis Type Detail | LC-MS |
| Release Date | 2016-06-18 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR000123 |
| Project DOI: | doi: 10.21228/M8PC7J |
| Project Title: | A targeted pharmacometabolomic investigation of the acylcarnitine pathway and incident impaired fasting glucose (IFG) |
| Institute: | University of Florida |
| Department: | Pharmacotherapy and Translational Research |
| Last Name: | Cooper-DeHoff |
| First Name: | Rhonda |
| Email: | dehoff@cop.ufl.edu |
Subject:
| Subject ID: | SU000157 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Human Inclusion Criteria: | Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose ? 100 mg/dl at the end of atenolol treatment are considered to have developed IFG. Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose that remained < 100 mg/dl at the end of atenolol treatment are considered to have not developed IFG. |
| Human Exclusion Criteria: | Participants with a fasting glucose ? 100 mg/dl at baseline are excluded from this study. |
| Species Group: | Human |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
| mb_sample_id | local_sample_id | Gender | Race |
|---|---|---|---|
| SA007499 | PE0077 | f | asian |
| SA007500 | PE0005 | f | black |
| SA007501 | PE0403 | f | black |
| SA007502 | PE0380 | f | black |
| SA007503 | PF0436 | f | black |
| SA007504 | PE0358 | f | black |
| SA007505 | PE0422 | f | black |
| SA007506 | PE0423 | f | black |
| SA007507 | PE0488 | f | black |
| SA007508 | PE0492 | f | black |
| SA007509 | PE0455 | f | black |
| SA007510 | PE0438 | f | black |
| SA007511 | PE0433 | f | black |
| SA007512 | PE0346 | f | black |
| SA007513 | PE0332 | f | black |
| SA007514 | PE0251 | f | black |
| SA007515 | PE0268 | f | black |
| SA007516 | PE0243 | f | black |
| SA007517 | PE0240 | f | black |
| SA007518 | PE0224 | f | black |
| SA007519 | PE0285 | f | black |
| SA007520 | PF0463 | f | black |
| SA007521 | PF0448 | f | black |
| SA007522 | PE0330 | f | black |
| SA007523 | PE0317 | f | black |
| SA007524 | PE0310 | f | black |
| SA007525 | PE0292 | f | black |
| SA007526 | PE0494 | f | black |
| SA007527 | PR0449 | f | black |
| SA007528 | PF0093 | f | black |
| SA007529 | PF0146 | f | black |
| SA007530 | PF0080 | f | black |
| SA007531 | PF0079 | f | black |
| SA007532 | PF0078 | f | black |
| SA007533 | PF0156 | f | black |
| SA007534 | PF0165 | f | black |
| SA007535 | PF0184 | f | black |
| SA007536 | PF0201 | f | black |
| SA007537 | PF0181 | f | black |
| SA007538 | PF0228 | f | black |
| SA007539 | PF0169 | f | black |
| SA007540 | PR0300 | f | black |
| SA007541 | PF0305 | f | black |
| SA007542 | PE0536 | f | black |
| SA007543 | PE0540 | f | black |
| SA007544 | PE0517 | f | black |
| SA007545 | PF0357 | f | black |
| SA007546 | PF0361 | f | black |
| SA007547 | PF0020 | f | black |
| SA007548 | PF0330 | f | black |
| SA007549 | PF0060 | f | black |
| SA007550 | PF0048 | f | black |
| SA007551 | PF0315 | f | black |
| SA007552 | PF0044 | f | black |
| SA007553 | PE0219 | f | black |
| SA007554 | PE0331 | f | black |
| SA007555 | PF0528 | f | black |
| SA007556 | PE0114 | f | black |
| SA007557 | PE0216 | f | black |
| SA007558 | PF0543 | f | black |
| SA007559 | PE0086 | f | black |
| SA007560 | PE0092 | f | black |
| SA007561 | PF0524 | f | black |
| SA007562 | PE0128 | f | black |
| SA007563 | PE0143 | f | black |
| SA007564 | PE0148 | f | black |
| SA007565 | PF0507 | f | black |
| SA007566 | PE0138 | f | black |
| SA007567 | PE0137 | f | black |
| SA007568 | PE0072 | f | black |
| SA007569 | PE0071 | f | black |
| SA007570 | PE0037 | f | black |
| SA007571 | PE0040 | f | black |
| SA007572 | PE0032 | f | black |
| SA007573 | PE0028 | f | black |
| SA007574 | PE0019 | f | black |
| SA007575 | PE0022 | f | black |
| SA007576 | PE0042 | f | black |
| SA007577 | PE0045 | f | black |
| SA007578 | PE0064 | f | black |
| SA007579 | PE0068 | f | black |
| SA007580 | PE0062 | f | black |
| SA007581 | PE0059 | f | black |
| SA007582 | PE0055 | f | black |
| SA007583 | PE0149 | f | black |
| SA007584 | PF0539 | f | black |
| SA007585 | PE0188 | f | black |
| SA007586 | PE0186 | f | black |
| SA007587 | PE0181 | f | black |
| SA007588 | PE0172 | f | black |
| SA007589 | PE0191 | f | black |
| SA007590 | PE0196 | f | black |
| SA007591 | PE0205 | f | black |
| SA007592 | PE0203 | f | black |
| SA007593 | PF0494 | f | black |
| SA007594 | PE0169 | f | black |
| SA007595 | PE0187 | f | black |
| SA007596 | PE0161 | f | black |
| SA007597 | PE0168 | f | black |
| SA007598 | PF0424 | f | black_hisp |
Collection:
| Collection ID: | CO000141 |
| Collection Summary: | At baseline and after completion of atenolol treatment, blood samples were collected and spun. Serum and plasma fractions were stored at -80C. 200 uL of plasma were aliquoted for metabolomics analyses. Sample Type: Blood serum Volume Collected: 200 uL |
| Sample Type: | Blood |
Treatment:
| Treatment ID: | TR000159 |
| Treatment Summary: | Atenolol was initiated at 50mg, and titrated to 100mg, based on BP > 120/70 mmHg and tolerability. Blood samples were collected prior to initiation of atenolol treatment and after at least 6 weeks on the final dose. Blood samples were spun and serum and plasma fractions stored at -80C. Treatment: Intervention Treatment Compound: Atenolol Treatment Dose: 50mg titrated to 100mg based on BP and tolerability Treatment Dose Duration: Minimum of 6 weeks |
Sample Preparation:
| Sampleprep ID: | SP000154 |
| Sampleprep Summary: | - |
| Sampleprep Protocol Filename: | Acylcarnitines_LCMSProtocol_SBMRI_ForSECIM_111714.docx |
Combined analysis:
| Analysis ID | AN000220 |
|---|---|
| Analysis type | MS |
| Chromatography type | Reversed phase |
| Chromatography system | Agilent 1290 Infinity |
| Column | Waters Acquity BEH C18 (100 x 2mm,1.7um) |
| MS Type | ESI |
| MS instrument type | Triple quadrupole |
| MS instrument name | Agilent 6490 QQQ |
| Ion Mode | POSITIVE |
| Units | uM |
Chromatography:
| Chromatography ID: | CH000152 |
| Instrument Name: | Agilent 1290 Infinity |
| Column Name: | Waters Acquity BEH C18 (100 x 2mm,1.7um) |
| Chromatography Type: | Reversed phase |
MS:
| MS ID: | MS000171 |
| Analysis ID: | AN000220 |
| Instrument Name: | Agilent 6490 QQQ |
| Instrument Type: | Triple quadrupole |
| MS Type: | ESI |
| Ion Mode: | POSITIVE |
